Mar. 5 at 5:54 PM
1/2
$ABUS now is not the time to sell. It’s time to double down. The market is essentially assigning a value of only
$500MM to ALL of: the 1498 appeal, the
$PFE $BNTX litigation, the equity in Genevant, future LNP royalties, AB-101, and AB-729.
Our direct and indirect share of
$950 is about
$300. This is guaranteed. Cash on hand is
$90. Current MC is
$900-
$400=EVERYTHING ELSE (
$500)
Remember that
$GSK paid
$1BLN for ARO-HBV (JNJ-3989) in late 2023 and AB-729 has (arguably) superior knockdown and functional cure rates in phase II studies (ie, well past proof of concept).
